Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
10.96M | 7.87M | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
1.54M | 795.00K | -222.00K | -484.00K | -368.00K | -103.00K | EBIT |
-206.36M | -592.63M | -99.82M | -119.73M | -93.32M | -43.55M | EBITDA |
-611.35M | -566.91M | -99.60M | -119.53M | -89.35M | -43.45M | Net Income Common Stockholders |
-606.38M | -567.94M | -75.80M | -88.66M | -79.73M | -39.50M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
461.68M | 502.69M | 611.21M | 661.01M | 765.39M | 215.75M | Total Assets |
492.49M | 540.63M | 621.48M | 672.14M | 776.15M | 221.79M | Total Debt |
11.41M | 8.91M | 4.01M | 4.26M | 3.06M | 0.00 | Net Debt |
-36.56M | -26.81M | -38.64M | -96.84M | -129.37M | -29.75M | Total Liabilities |
73.03M | 76.84M | 16.36M | 17.07M | 30.15M | 6.71M | Stockholders Equity |
419.46M | 463.79M | 605.12M | 655.08M | 746.00M | 215.08M |
Cash Flow | Free Cash Flow | ||||
-114.85M | -130.57M | -68.07M | -96.48M | -68.47M | -36.67M | Operating Cash Flow |
-114.71M | -130.41M | -68.00M | -96.11M | -68.19M | -36.53M | Investing Cash Flow |
169.34M | 122.70M | 8.92M | 63.46M | -454.67M | -70.32M | Financing Cash Flow |
858.00K | 331.00K | 628.00K | 1.33M | 625.53M | 133.13M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $892.37M | ― | -63.56% | ― | 270.02% | 32.69% | |
54 Neutral | $5.34B | 3.27 | -45.10% | 3.30% | 16.80% | 0.02% | |
52 Neutral | $654.06M | ― | -33.48% | ― | -25.88% | -29.16% | |
50 Neutral | $676.09M | ― | -79.02% | ― | -50.69% | 8.01% | |
48 Neutral | $545.36M | ― | 34.94% | ― | ― | ― | |
45 Neutral | $632.89M | ― | -119.66% | ― | ― | -551.08% | |
40 Underperform | $315.67M | ― | -60.45% | ― | ― | 6.99% |
On February 12, 2025, Dr. Jerry Wang, CEO of AnHeart Therapeutics, a subsidiary of Nuvation Bio Inc., departed the company after achieving key goals, including regulatory approvals for taletrectinib in China and the U.S., and the integration of AnHeart Therapeutics post-merger. Dr. Wang’s departure was not due to any disagreements, and his role as CEO was deemed unnecessary following these accomplishments.